NCT04699279 Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)
| NCT ID | NCT04699279 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing Medical University |
| Condition | Acute Aortic Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2021-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute Aortic Syndrome (AAS)/Aortic Aneurysm is a common feature of aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, the authors hypothesized that people with acute aortic syndrome but without hyperlipidemia might benefit from statin treatment.
Eligibility Criteria
Inclusion Criteria: * (1) Patients with aortic dissection/ulceration/intermural hematoma/aortic aneurysm who underwent aortic arch replacement or endoluminal isolation or hybrid therapy; * (2) Paitents without clinically significant hyperlipidemia but with cardiovascular disease risk factors (such as male ≥45 years old, female ≥55 years old, hypertension, diabetes, chronic kidney disease, obesity, low HDL cholesterol, smoking, alcohol consumption, family history of early onset ischemic cardiovascular disease) and no previous use of statins; * (3) Patients are between 18 and 85 years old, male or female; * (4) Agree to participate in the study and sign the informed consent. Exclusion Criteria: * (1) Patients with allergy to statins; * (2) patients with active liver disease; * (3) patients with myopathy; * (4) Lactating women and pregnant women; * (5) Patients with mental diseases, drug and alcohol dependence; * (6) Refuse to participate in the study or sign the informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04699279 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Acute Aortic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04699279 currently recruiting?
Yes, NCT04699279 is actively recruiting participants. Contact the research team at DR.HONGLIU@FOXMAIL.COM for enrollment information.
Where is the NCT04699279 trial being conducted?
This trial is being conducted at Guangzhou, China, Nanjing, China, Qingdao, China, Chengdu, China and 1 additional location.
Who is sponsoring the NCT04699279 clinical trial?
NCT04699279 is sponsored by Nanjing Medical University. The trial plans to enroll 300 participants.